- Health Canada has approved biotech giant Moderna’s (NASDAQ:MRNA) updated COVID-19 vaccine for all Canadians 6 months and older
- The mRNA-based shot is monovalent, targeting just the Omicron XBB.1.5 subvariant, which means the vaccine is more tailored to the virus strains currently circulating
- Clinical trials showed that beginning two weeks after the second dose, the Moderna Spikevax COVID vaccine was 94.1 per cent effective in protecting trial participants aged 18 and above against COVID-19 and 100 per cent effective in trial participants 12 to 17 years old
- Moderna Inc. closed trading down 0.53 per cent at US $105.24 per share
Health Canada has approved biotech giant Moderna’s (NASDAQ:MRNA) updated COVID-19 vaccine for all Canadians 6 months and older.
Its safety and effectiveness in people younger than 6 months have not yet been established.
The mRNA-based shot is monovalent, targeting just the Omicron XBB.1.5 subvariant, which means the vaccine is more tailored to the virus strains currently circulating.
According to Health Canada, clinical trials showed that beginning two weeks after the second dose, the Moderna Spikevax COVID vaccine was 94.1 per cent effective in protecting trial participants aged 18 and above against COVID-19 and 100 per cent effective in trial participants 12 to 17 years old.
Earlier this week, the U.S. Food and Drug Administration approved a supplemental Biologics License Application (sBLA) for Spikevax for ages 12 and above.
For more on Canada’s top biotech stocks – Best biotech stocks to buy in 2023
Moderna Inc. is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators.
Moderna Inc. closed trading down 0.53 per cent at US$105.24 per share.
Join the discussion: Find out what everybody’s saying about this stock on Moderna’s Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.